Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
about
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureusIn vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strainsSusceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenemIn vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rodsLevofloxacin and sparfloxacin: new quinolone antibiotics.Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid.Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.Coagulase-negative staphylococci isolated from various skin lesions.
P2860
Q28379074-DF727467-E915-4A97-B77C-0671F1B22B76Q28379294-0E2C0A20-1E13-4585-AD68-3180CE7AAC08Q35123308-7EAC06B4-6AB0-42F4-9589-4F3804E57CB6Q35123438-1A1D6442-C98C-40B7-AE70-9A7D08CD10EAQ35125533-241D16C5-DC19-4059-B854-D7D1CE7591A9Q35136059-E3443C0A-4608-4051-8A55-47D7EBE35502Q35137076-DC4C2CAC-6F4A-45E8-AF63-869FF09E8FDBQ37881273-D21CD67B-5CDB-47F2-82CD-DC82D1E026D7Q39781018-D257412E-FF8C-459B-86F1-58C0DE356CE5Q40882790-56BFFBC0-4DEA-4C2E-A599-CA7F35334D6EQ45137202-71C5B103-B125-4D8F-A888-CE48ED6A92DBQ46523757-5205C958-890B-4487-9E99-8B66EED22692Q54118758-3C562BF2-C368-4613-BE9C-B75161620ABE
P2860
Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Susceptibilities of bacterial ...... floxacin and other quinolones.
@ast
Susceptibilities of bacterial ...... floxacin and other quinolones.
@en
type
label
Susceptibilities of bacterial ...... floxacin and other quinolones.
@ast
Susceptibilities of bacterial ...... floxacin and other quinolones.
@en
prefLabel
Susceptibilities of bacterial ...... floxacin and other quinolones.
@ast
Susceptibilities of bacterial ...... floxacin and other quinolones.
@en
P2093
P2860
P356
P1476
Susceptibilities of bacterial ...... floxacin and other quinolones.
@en
P2093
P2860
P304
P356
10.1128/AAC.38.4.848
P407
P577
1994-04-01T00:00:00Z